Immune Basis of New MS Therapies
|
|
- Randolph Dickerson
- 8 years ago
- Views:
Transcription
1 Immune Basis of New MS Therapies Samia J Khoury, MD Director of Abou-Haidar Neuroscience Institute Director of Multiple Sclerosis Center Professor of Neurology AUBMC MS Center & Harvard Medical School
2 Circulation Of Activated Cells To The CNS SERUM Recruitment of Ag non-specific cells CNS Demyelination Activated Cells CNS Ag-specific cell persists Interaction with endothelium Recirculates Non-CNS specific Cell
3 Frequency Of Autoreactive T Cells T Cells recognizing MBP and PLP are present in normal individuals No difference in the frequency of these cells between MS patients and normal individuals The frequency of activated MBP, and PLP but not tetanus toxoid lines was significantly higher in MS patients
4 Activation Of T Cells Binding of TCR to Ag/APC leads to a series of intracellular events that result in transcription of a variety of genes by the T cell Signaling through the TCR is not sufficient for activation to occur. A second signal is required such as binding of CD28 to B7 molecules.
5 How Do Autoreactive T Cells Become Activated Molecular mimicry: antigenic epitopes of an infectious agent mimic a self protein epitope. Superantigens: bind to Class II MHC and specific TCR Vβ segments and may occur during the course of a bacterial or viral infection.
6 Observation in patients with MS: There is clonal expansion and persistence of autoreactive T cells 3) IL-12 2) B7 CD28 APC THP 1) Engagement of T cell receptor by crossreactive microbial antigen autoreactive autoreactiv autoreactiv e TH1 e autoreactiv auto- TH1 e TH1 TH1 reactive
7 Activated Autoreactive T cells expressing VLA-4 adhere to endothelium via interactions with VCAM and enter into the tissue 3) IL-12 VCAM Inflammed Tissue 2) B7 CD28 TH P TH1 autoreactive autoreactive autoreactive TH1 1) Engagement of T cell receptor by crossreactive microbial antigen VLA-4 autoreactive TH1 Peripheral Immune System
8 Activated autoråeactive T cells enter into tissue, recognize self antigen presented by local APC with costimulation and induce inflammation 3) IL-12 2) B7 CD28 auto-reactive IL-2 IFN-γ TNF-α CD28 B7 TH P 1) Engagement of T cell receptor by crossreactive microbial antigen Peripheral Immune System autoreactive TH1 CD154 CD40 IL-12 tissue APC autoantigens Tissue Damage
9 Inflamed tissue becomes source of antigen, epitope spreading occurs 2) B7 3) IL-12 CD28 autoreactive A A autoreactive A TH1 CD28 B7 tissue APC 1) Engagement of T cell receptor by crossreactive microbial antigen Peripheral Immune System autoreactive B CD28 B7 TH1 IL-2 CD154 CD40 IFN-γ TNF-α IL-12 Epitope Spreading tissue APC autoantigens
10 Th subsets Awasthi, A. et al. Int. Immunol :dxp021v2-21; doi: /intimm/dxp021 Copyright restrictions may apply.
11 A Model of Immune Mechanisms in MS: Overview
12 Immune Status and Disease Course in MS Adaptive Immunity (Antigen-specific T cells, B cells) Relapsing-remitting GD enhancement
13 Immune Status and Disease Course in MS Innate Immunity (Microglia, monocytes, dendritic cells) Adaptive Immunity (Antigen-specific T cells, B cells) Disability GD enhancement Relapsing-remitting Secondary progressive
14 Natalizumab (Tysabri) 3 of approximately 3000 treated patients (MS, Crohn s and RA) developed progressive multifocal leukoencephalopathy (PML). 2 of the cases were fatal. Crohn s patient - prior hx of Azathioprine treatment - fatal MS patient - treated with Natalizumab+Avonex - fatal MS patient - treated with Natalizumab+Avonex recovering resulted in the suspension of the drug - Feb FDA re-approved Tysabri in July 2006 Since reintroduction of Tysabri 56,500 patients have been treated and 10 cases of PML have been confirmed
15 Natalizumab (Tysabri) - PML PML is a demyelinating disease of the CNS caused by lytic infection of oligodendrocytes by JC polyomavirus Primary JC viral infection occurs in childhood and is asymptomatic JC virus normally resides in the kidney and lymphoid organs Antibodies to JC virus are detectable in 50-70% of adults B cells may deliver the virus to the CNS PML can occur in immunocompromised patients (AIDS, immunosuppressive medications, transplant patients) No prior association of PML and MS Theories why Natalizumab treatment led to PML Reactivation of the virus in the periphery Organ-specific immunosuppression Generalized immunosuppression Suppression of immune surveillance in CNS by viral-reactive CD8+ cells Increased/dysregulated delivery of virus to the CNS
16 PML Risk Stratification
17 Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells IFN-γ Baseline Months FL2-H: TNFa FL2-H: TNFa TNF FL2-H: TNFa FL2-H: TNFa IL FL2-H: TNFa FL2-H: TNFa Kivisakk et al. Neurology 2009;72:
18 Fingolimod Synthetic analogue of fungal (Isaria sinclairii) metabolite ( Myoricin ) FTY720 Fujita et al. J Antibiot 1994;47:208 15
19 Widespread Expression of S1PR
20 Adaptive immunity depends on regular circulation of lymphocytes between blood and lymphoid tissue in the search for antigens. When an activating antigen is encountered in the lymph nodes, expression of S1P1 on T cells is transiently downregulated, allowing the T cells to remain in contact with antigen-presenting cells and to become activated. Retention in lymphoid tissues and recirculation of lymphocytes back to the blood circulation is regulated in part by a concentration gradient of S1P between lymphoid tissues and other tissues or body fluids, which is sensed through S1P1R expressed on lymphocytes Following activation, cell-surface expression of S1P1 is upregulated, allowing cells to respond to the S1P gradient and exit the lymph node
21 S1P signaling regulates the egress of lymphocytes from LN
22 Fingolimod selectively retains only lymphocytes that regularly traffic through lymphoid tissues
23
24 Fingolimod Mechanisms
25 Alemtuzumab Monoclonal Antibody for CD52 expressed on essentially all B and T cells, monocytes, macrophages, NK cells and some granulocytes Approved for B-CLL, Phase II for MS Benefits: 75% reduction in relapse rate compared to REBIF (IFN-β 1a) 60% reduction in risk of progression of disability Risks: Dosing halted due to 3 cases of confirmed ITP A separate study suggest high risk (30%) of Graves Disease Hematologic Toxicity: Pancytopenia Risk of Opportunistic Infections Phase 3 ongoing
26 Alemtuzumab
27
28 Mechanisms of autoimmune disease emergence after Alemtuzumab Monocytes return to normal within 3 months B cell counts return to baseline numbers by 3 months and are then increased to about 124% of pre-treatment levels T cell counts recover much slower: depletion of CD4+ cells lasts a median of 61 months and of CD8+ cells for 30 months The observed enhanced antibody-mediated autoimmunity might be related to enhanced B cell function in the state of lymphopenia. Patients who developed autoimmunity were noted to have enhanced production of IL-21, that may promote autoimmunity by various mechanisms, such as TH17 induction, and promotion of B cell differentiation and antibody production
29 Daclizumab
30 Hypothesized Immunomodulatory Effect of Daclizumab Treatment
31 Additional mechanisms of Daclizumab anti-cd25 interferes with early dendritic cell-t cell interaction anti-cd25 treatment interferes with CD40L expression CD25high T regulatory (Treg) cells are slightly diminished in frequency and possibly also in their function
32 Daclizumab high-yield process in RRMS (SELECT)
33 Daclizumab high-yield process in RRMS (SELECT)
34 Dimethylfumarate-BG12
35 Immune Mechanisms of Dimethylfumarate Nrf-2 (nuclear factor E2(erythroid-derived 2)-related factor) which is released from binding to Keap-1 via the activity of fumarates. Nrf-2 in turn upregulates an array of antioxidative pathways such as increased glutathione levels. These also lead to an inhibition of the translocation of NF-κB into the nucleus Decreased expression of NF-κB-dependent genes that regulate the expression of a cascade of inflammatory cytokines, chemokines, and adhesion molecules. DMF can induce apoptosis in human T-cells may shift the cytokine profile from a TH1 to a TH2 profile.
36 Effect of Dimethylfumarate on various cells Cell type Effect T cells B cells Dendritic Cells Glia Endothelial cells Apoptosis TH1 to TH2 shift Apoptosis Inhibition of differentiation Downregulation of TH1 response Inhibition of proinflammatory cytokines Inhibition of TNF-a, ICAM-1, E-selectin, VCAM-1
37 A. The initial MRI B & C. On follow-up 2 and 3 months later D. On follow-up at 3 months, enhancing lesions suggestive of the immune reconstitution inflammatory syndrome (IRIS).
38 Terflunomide: Mechanism of Action
39 TEMSO Trial N Engl J Med 2011;365:
40 TEMSO Trial N Engl J Med 2011;365:
41 N Engl J Med 2011;365:
42 Laquinimod Laquinimod is an orally administered compound that is structurally related to linomide Laquinimod appears to have some ability to penetrate the CNS, with 7% 8% penetrance reported in healthy SJL/N mice and 13% in EAE as measured by 14C labeled laquinimod The therapeutic mode of action of laquinimod in MS is not fully understood
43 B cell functions
44 B cell directed therapies
45 Therapeutic recombinant antibodies Nomenclature
46 PML Risk in Autoimmune Disease Therapy Estimated incidence 1 case per individuals with RA treated with Rituximab Worldwide, there were seventeen cases of PML that are potentially associated with MMF in lupus patients. Pre-B cells that harbor JCV in a latent state may be released into circulation to repopulate B-cell functions after differentiation 3 patients had JCV detected in paraffin-fixed bone marrow samples obtained years before rituximab administration. JCV latency may be more relevant for natalizumab-treated patients because CD34+ cells have been shown to mobilize into the peripheral circulation upon initiation of treatment
47 Alemtuzumab
48 The CAMMS223 Trial Investigators. N Engl J Med 2008;359:
49 The CAMMS223 Trial Investigators. N Engl J Med 2008;359:
50 Laquinimod: Mechanisms of Action
51 CTLA4Ig Inhibition of the Immune Response CD28 on the surface of T cells interacts with CD80 and CD86 on the surface of antigen presenting cells to provide a costimulatory signal
52 Mechanism of CTLA4Ig Inhibition of The Immune Response
53 CTLA4Ig treatment in patients with MS An open-label, phase 1 clinical trial Th2/Th1 MBP (20µg/ml) BL 8D M1 M2 M3 CTLA-4Ig infusion Viglietta et al. Neurology 2008;71:
54 ITN035AI Khoury - ACCLAIM - Phase II Trial A Phase II, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept (CTLA4-Ig) in Adults with Multiple Sclerosis The study is sponsored by the National Institute of Allergy and Infectious Diseases (a part of the National Institutes of Health) and the non-profit Immune Tolerance Network
55 Therapeutic Approaches for the Treatment of MS Decrease Th1/Th17 Induce Tregs Prevent lymphocyte trafficking Deplete B cells Affect innate immunity Provide neuroprotection Promote remyelination
56
Frequency Of Autoreactive T Cells 3/5/2014. Circulation Of Activated Cells To The CNS
Immune Basis of New MS Therapies Samia J Khoury, MD Director of Abou-Haidar Neuroscience Institute Director of Multiple Sclerosis Center Professor of Neurology AUBMC MS Center & Harvard Medical School
More informationNew Treatment Options for MS Patients: Understanding risks versus benefits
New Treatment Options for MS Patients: Understanding risks versus benefits By Michael A. Meyer, MD Department of Neurology, Sisters Hospital, Buffalo, NY Objectives: 1. to understand fundamentals of MS
More informationThis information can also be found in the Summit 2011 Program on page 8.
If you would like to receive CME credit for this activity, please visit: http://www.pesgce.com/pvasummit2011/ This information can also be found in the Summit 2011 Program on page 8. Newer Treatments:
More informationNews on modifying diseases therapies. Michel CLANET CHU Toulouse France ECTRIMS
News on modifying diseases therapies Michel CLANET CHU Toulouse France ECTRIMS Current treatment strategies Future oral treatments Future non oral treatments Drug safety and risks CIS at risk of MS Active
More informationUnderstanding How Existing and Emerging MS Therapies Work
Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of
More informationThe Immunopathogenesis of Relapsing MS
The Immunopathogenesis of Relapsing MS Olaf Stüve, M.D., Ph.D. Neurology Section VA North Texas Health Care System Dallas VA Medical Center Departments of Neurology and Neurotherapeutics University of
More informationPersonalised Medicine in MS
Personalised Medicine in MS Supportive Evidence from Therapeutic Trials Ludwig Kappos Neurology and Department of Biomedicine University Hospital CH-4031 Basel LKappos@uhbs.ch Established partially effective
More informationspecific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins
Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes
More informationAutoimmunity and immunemediated. FOCiS. Lecture outline
1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic
More informationThe immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor
The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationChapter 43: The Immune System
Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2
More informationB Cells and Antibodies
B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production
More informationEMA and Progressive Multifocal Leukoencephalopathy.
EMA and Progressive Multifocal Leukoencephalopathy. ENCePP Plenary, London 23 November 2011 Presented by: Henry Fitt Head of Coordination & Networking, Pharmacovigilance & Risk Management An agency of
More informationNatalizumab (Tysabri) and PMLthe current figures. Paul-Ehrlich-Institut Brigitte Keller Stanislawski Paul-Ehrlich-Str. 51-59 63225 Langen GERMANY
Natalizumab (Tysabri) and PMLthe current figures Paul-Ehrlich-Institut Brigitte Keller Stanislawski Paul-Ehrlich-Str. 51-59 63225 Langen GERMANY Humanised MAB Natalizumab Specific binding to a4-integrin
More informationFuture therapies in multiple sclerosis
Neurology Asia 2008; 13 : 189 193 Future therapies in multiple sclerosis David Bates Department of Neurology, University of Newcastle upon Tyne, UK Abstract It is now 15 years since the first disease modifying
More informationImmunosuppressive drugs
Immunosuppressive drugs RJM ten Berge Afd. Inw. Geneeskunde AMC contents overview targets mechanism of action Effects on immune capacity measured by responses to vaccination Immune response 1 calcineurin
More informationCompositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study
Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study Nele Claes 1 *; Tessa Dhaeze 1 *; Judith Fraussen PhD 1 ; Bieke Broux
More informationNew Therapies in MS: Filling up the spaces. Eli Silber Consultant Neurologist Kings College Hospital
New Therapies in MS: Filling up the spaces Eli Silber Consultant Neurologist Kings College Hospital What is wrong with the current therapies? The current therapies have limited efficacy 1 st line relapse
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationDrug Class Review. Disease-modifying Drugs for Multiple Sclerosis. Single Drug Addendum: Fingolimod
Drug Class Review Disease-modifying Drugs for Multiple Sclerosis Single Drug Addendum: Fingolimod Final Original Report February 2011 The Agency for Healthcare Research and Quality has not yet seen or
More informationIntegrating New Treatments: A Case Based Approach
Integrating New Treatments: A Case Based Approach JILL CONWAY, MD, MA, MSCE DIRECTOR, MS CENTER DIRECTOR, NEUROLOGY CLERKSHIP AT UNCSOM- CHARLOTTE CAMPUS CAROLINAS HEALTHCARE CENTER Objectives Provide
More informationNew treatments in MS What s here and what s nearly here
5 th MS Research Day, June 14 th 2014 New treatments in MS What s here and what s nearly here David Miller Queen Square MS Centre at UCL and UCLH Course of MS and its treatment Relapsing remitting Disability
More informationNovel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?
Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International
More informationThe Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences
The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for
More informationLaquinimod Polman, C. et al. Neurology 2005;64:987-991
Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Multicenter, double-blind, randomized trial, patients with RR MS received 0.1 mg or 0.3 mg laquinimod or placebo as three daily tablets for 24 weeks
More informationNatalizumab (Tysabri)
Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationB Cell Generation, Activation & Differentiation. B cell maturation
B Cell Generation, Activation & Differentiation Naïve B cells- have not encountered Ag. Have IgM and IgD on cell surface : have same binding VDJ regions but different constant region leaves bone marrow
More informationNatalizumab and the Risk of PML
Natalizumab and the Risk of PML Gloria von Geldern, MD Multiple Sclerosis Center Assistant Professor of Neurology University of Washington May 13, 2015 Conflict of Interest Dr. von Geldern has nothing
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF I. Requirements for Prior Authorization of Tysabri A. Prescriptions That Require Prior Authorization All prescriptions for Tysabri must be prior authorized.
More informationMicrobiology AN INTRODUCTION EIGHTH EDITION
TORTORA FUNKE CASE Microbiology AN INTRODUCTION EIGHTH EDITION Differentiate between innate and acquired immunity. Chapter 17 Specific Defenses of the Host: The Immune Response B.E Pruitt & Jane J. Stein
More informationB cell activation and Humoral Immunity
B cell activation and Humoral Immunity Humoral immunity is mediated by secreted antibodies and its physiological function is defense against extracellular microbes (including viruses) and microbial exotoxins.
More informationThe Immune System: A Tutorial
The Immune System: A Tutorial Modeling and Simulation of Biological Systems 21-366B Shlomo Ta asan Images taken from http://rex.nci.nih.gov/behindthenews/uis/uisframe.htm http://copewithcytokines.de/ The
More informationT Cell Maturation,Activation and Differentiation
T Cell Maturation,Activation and Differentiation Positive Selection- In thymus, permits survival of only those T cells whose TCRs recognize self- MHC molecules (self-mhc restriction) Negative Selection-
More informationThe following MS experts were involved in the development of this Position Statement:
Position Statement for TYSABRI (natalizumab) and STRATIFY JCV TM in Multiple Sclerosis Rationale for this Position Statement This Position Statement was developed by ten Australian neurologists who specialise
More informationFORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September
More informationClinical Trials of Disease Modifying Treatments
MS CENTER CLINICAL RESEARCH The UCSF MS Center is an internationally recognized leader in multiple sclerosis clinical research. We conduct clinical trials involving the use of experimental treatments,
More informationANIMALS FORM & FUNCTION BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES. Animals Form & Function Activity #4 page 1
AP BIOLOGY ANIMALS FORM & FUNCTION ACTIVITY #4 NAME DATE HOUR BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES Animals Form & Function Activity #4 page 1 INFLAMMATORY RESPONSE ANTIMICROBIAL
More informationUncertainty in Benefit and Risk: Tysabri (natalizumab)
Uncertainty in Benefit and Risk: Tysabri (natalizumab) Robert J. Temple, M.D. Deputy Center Director for Clinical Science Center for Drug Evaluation and Research U.S. Food and Drug Administration IOM Drug
More informationFocus on CNS Drug Development Treating secondary progressive multiple sclerosis. Simon Wilkinson, CEO
Focus on CNS Drug Development Treating secondary progressive multiple sclerosis Simon Wilkinson, CEO Forward Looking Statements 2 This Presentation (and any financial information that may be provided by
More informationNew approaches in the management of multiple sclerosis
Drug Design, Development and Therapy open access to scientific and medical research Open Access Full Text Article New approaches in the management of multiple sclerosis Review Laurie J Barten 1 Douglas
More informationAutoimmunity. Autoimmunity. Genetic Contributions to Autoimmunity. Targets of Autoimmunity
Autoimmunity Factors predisposing an individual to autoimmune disease Mechanisms of initiation of autoimmunity Pathogenesis of particular autoimmune disease Animal models of autoimmune disease Treatment
More informationJournal Club: Therapies for Multiple Sclerosis
Journal Club: Therapies for Multiple Sclerosis Sashank Prasad, MD Brigham and Women s Hospital Boston, MA Learning Objectives 1. Become familiar with recent risk estimates for progressive multifocal leukoencephalopathy
More informationJournal of Central Nervous System Disease
Journal of Central Nervous System Disease Expert Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. New and Emerging Disease-Modifying Therapies for Relapsing-Remitting
More informationNew research in primary and secondary progressive multiple sclerosis. Dr Claire McCarthy MRCP PhD Neurology SpR Addenbrooke s Hospital
New research in primary and secondary progressive multiple sclerosis Huntingdon MS Society Annual Meeting Sat 22nd March 2014 Dr Claire McCarthy MRCP PhD Neurology SpR Addenbrooke s Hospital 1 Overview
More informationMultiple Sclerosis: An imaging review and update on new treatments.
Multiple Sclerosis: An imaging review and update on new treatments. Dr Marcus Likeman Consultant Neuroradiologist North Bristol NHS Trust Bristol Royal Hospital for Children MRI appearances - White Matter
More informationNew Developments in the Treatment and Management of Multiple Sclerosis
New Developments in the Treatment and Management of Multiple Sclerosis Myla D. Goldman, MD, MS For a CME/CEU version of this article, please go to www.namcp.org/cmeonline.htm, and then click the activity
More informationMultiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center
Multiple Sclerosis Update Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center None Disclosures First of All. Why is my talk in the Neurodegenerative hour? I respectfully object! Case
More informationNational MS Society Information Sourcebook www.nationalmssociety.org/sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers
More informationA neurologist would assess your eligibility and suitability for the DMTs.
Choices Disease Modifying Treatments Disease modifying treatments (DMTs) are medications which modify the disease course. They target inflammation and are designed to reduce the damage caused by relapses.
More informationThe Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.
The Most Common Autoimmune Disease: Rheumatoid Arthritis Bonita S. Libman, M.D. Disclosures Two googled comics The Normal Immune System Network of cells and proteins that work together Goal: protect against
More informationDisease Modifying Therapies (DMTs) in Multiple Sclerosis
Disease Modifying Therapies (DMTs) in Multiple Sclerosis Gary Stobbe, MD Medical Director, MS Project ECHO Clinical Assistant Professor, UW Neurology Conflict of Interest Dr. Stobbe has no conflicts of
More informationName (print) Name (signature) Period. (Total 30 points)
AP Biology Worksheet Chapter 43 The Immune System Lambdin April 4, 2011 Due Date: Thurs. April 7, 2011 You may use the following: Text Notes Power point Internet One other person in class "On my honor,
More informationDendritic Cells: A Basic Review *last updated May 2003
*last updated May 2003 Prepared by: Eric Wieder, PhD MD Anderson Cancer Center Houston, TX USA What is a dendritic cell? Dendritic cells are antigen-presenting cells (APCs) which play a critical role in
More informationPrograma Cooperación Farma-Biotech Neurociencias NT-KO-003
Programa Cooperación Farma-Biotech Neurociencias NT-KO-003 A new oral treatment for Multiple Sclerosis based on a novel mechanism of action Barcelona, 15 de febrero 2011 Programa Cooperación Farma-Biotech
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationNatalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia
Pathogenesis of Dengue Natalia Taborda Vanegas Doc. Sci. Student Immunovirology Group Universidad de Antioquia Infection process Epidermis keratinocytes Dermis Archives of Medical Research 36 (2005) 425
More informationImmunology and immunotherapy in allergic disease
Immunology and immunotherapy in allergic disease Jing Shen, MD Faculty Advisor: Matthew Ryan, MD The University of Texas Medical Branch Department of Otolaryngology Grand Rounds Presentation February 2005
More informationMolecular Pathology of MS: Signposts to new Therapy Hans Lassmann (MD)
Brain Research Center Medical University of Vienna Molecular Pathology of MS: Signposts to new Therapy Hans Lassmann (MD) IMMUNOLOGY OF MULTIPLE SCLEROSIS Noseworthy et al 2000 NEJM Immunomodulatory Treatment
More informationDrug Development Services
Drug Development Services USING BLOOD AND BONE MARROW PRIMARY CELL SYSTEMS Clinically Relevant In Vitro Assays Broad Spectrum of Drug Classes Multi-Species Platforms Enhancing Drug Development through
More informationOptimal R&D Allocation Modern Portfolio Theory. Efficient F R O N T I E R. Ryan Catania, Jacqueline Heiss, Xiaoting Huo, Dan Su, Cheng Yang
& Optimal R&D Allocation Modern Portfolio Theory Efficient F R O N T I E R Ryan Catania, Jacqueline Heiss, Xiaoting Huo, Dan Su, Cheng Yang Multiple Sclerosis - Pathophysiology T Cell Barrier Antigen Presenting
More informationManaging Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre
Managing Relapsing Remitting MS Risks & benefits of emerging therapies Dr Mike Boggild The Walton Centre MS: Facts and figures Affects 1 in 800 in the UK Commonest cause of acquired neurological disability
More informationEffective for dates of service on or after January 1, 2015 refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm
Effective for dates of service on or after January 1, 2015 refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Tysabri (natalizumab) Policy #: 281 Latest Review Date: October
More informationActivation and effector functions of HMI
Activation and effector functions of HMI Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 25 August 2015 ว ตถ ประสงค หล งจากช วโมงบรรยายน แล วน กศ กษาสามารถ
More informationRecruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed
Apitope study The study drug (ATX-MS-1467) is a new investigational drug being tested as a potential treatment for relapsing forms of multiple sclerosis (RMS). The term investigational drug means it has
More informationOverview. Transcriptional cascades. Amazing aspects of lineage plasticity. Conventional (B2) B cell development
Overview B cell development Transcriptional cascades Amazing aspects of lineage plasticity Conventional (B2) B cell development What happens to an autoreactive B cell? B1 vs B2 cells Key anatomical sites
More informationDimethyl fumarate and progressive multifocal leucoencephalopathy (PML)
Dimethyl fumarate and progressive multifocal leucoencephalopathy (PML) Introduction Dimethyl fumarate Psorinovo is not registered through the Medicines Evaluation Board (MEB). It is a compounded drug made
More information2) Macrophages function to engulf and present antigen to other immune cells.
Immunology The immune system has specificity and memory. It specifically recognizes different antigens and has memory for these same antigens the next time they are encountered. The Cellular Components
More informationProgress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
More informationThe Prospect of Stem Cell Therapy in Multiple Sclerosis. Multiple sclerosis is a multifocal inflammatory disease of the central
The Prospect of Stem Cell Therapy in Multiple Sclerosis Multiple sclerosis is a multifocal inflammatory disease of the central nervous system that generally affects young individuals, causing paralysis
More information- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif -
PRESS RELEASE Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada TM* (Alemtuzumab) Compared With Rebif in Phase lll Trial - Patients treated with
More informationAltered Immune Response in MS
How do the Current DMT s Affect the Altered Immune Response in MS Scott Newsome, D.O. Assistant Professor of Neurology Director, Neurology Outpatient Services Johns Hopkins University School of Medicine
More informationImmune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association
Immune modulation in rheumatology Geoff McColl University of Melbourne/Australian Rheumatology Association A traditional start to a presentation on biological agents in rheumatic disease is Plasma cell
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Gold R, Giovannoni G, Selmaj K, et al, for
More informationALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES
ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES DESCRIPTION OF GRANT MECHANISM The Alliance for Lupus Research (ALR) is an independent,
More informationMultiple sclerosis disease-modifying drugs second line treatments
Great Ormond Street Hospital for Children NHS Foundation Trust: Information for Families Multiple sclerosis disease-modifying drugs second line treatments The following information should be read in conjunction
More informationGenzyme s Multiple Sclerosis Franchise Featured at AAN
PRESS RELEASE Genzyme s Multiple Sclerosis Franchise Featured at AAN - Multiple Presentations Highlight Continuing Progress of AUBAGIO and LEMTRADA Programs - Paris, France March 13, 2013 Sanofi (EURONEXT:
More informationWhat is Multiple Sclerosis? Disease Modifying Therapies. Best of all. Why is treatment so important? Outline and Expectations.
What is Multiple Sclerosis? Disease Modifying Therapies for Relapsing Remitting MS Jeanie Lynn Cote, MD Chronic, auto immune disorder. As a consequence of immune attacks, there is loss of myelin (fatty
More informationHapten - a small molecule that is antigenic but not (by itself) immunogenic.
Chapter 3. Antigens Terminology: Antigen: Substances that can be recognized by the surface antibody (B cells) or by the TCR (T cells) when associated with MHC molecules Immunogenicity VS Antigenicity:
More informationTYSABRI Risk Management Plan. Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc
76 TYSABRI Risk Management Plan Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc 77 Presentation Outline Overview and Goals of Plan Risk Minimization Plan Risk Assessment
More informationClinical relevance of natalizumab tests for multiple sclerosis
22-09-08 Clinical relevance of natalizumab tests for multiple sclerosis Theo Rispens Multiple Sclerosis Treatment of (relapsing-remitting) MS 1 st line IFN-β (Avonex, Rebif, Betaferon) Glatiramer acetate
More informationChapter 10. Summary & Future perspectives
Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral
More informationGrowth in revenue from MS drugs has been driven largely by price increases over the last several years.
March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera
More informationGuidance for evaluation of new neurological symptoms in patients receiving TYSABRI
Guidance for evaluation of new neurological symptoms in patients receiving TYSABRI Background information Progressive multifocal leukoencephalopathy (PML) PML is a demyelinating disease that attacks the
More informationOne of the more complex systems we re looking at. An immune response (a response to a pathogen) can be of two types:
Immune system. One of the more complex systems we re looking at. An immune response (a response to a pathogen) can be of two types: (pathogen - disease causing organism) 1) Non specific. Anything foreign
More informationRELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010
RELAPSE MANAGEMENT Pauline Shaw MS Nurse Specialist 25 th June 2010 AIMS OF SESSION Relapsing/Remitting MS Definition of relapse/relapse rate Relapse Management NICE Guidelines Regional Clinical Guidelines
More informationHas the medication received FDA approval? Yes the FDA approved dimethyl fumarate on March 27, 2013.
Dimethyl Fumarate [formerly called BG-12] (Tecfidera ) CLINICIAN INFORMATION What is the medication? April 2013 Generic: Dimethyl Fumarate [formerly called BG-12] Brand name: Tecfidera The third oral medication
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationA Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
More informationFactors that Lead to the Immunotherapy Gap in Multiple Sclerosis Testing by Karthika Solai
Factors that Lead to the Immunotherapy Gap in Multiple Sclerosis Testing by Karthika Solai Introduction Multiple sclerosis is a disease that affects the central nervous system. Most doctors and scientists
More informationFORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011
More informationImmuno-Oncology Therapies to Treat Lung Cancer
Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own
More informationOpportunistic Infections Related to Immune Suppressant and Biologic Drug Therapy in IBD
Opportunistic Infections Related to Immune Suppressant and Biologic Drug Therapy in IBD Raymond Cross, M.D., M.S., AGAF Associate Professor of Medicine Director of the Inflammatory Bowel Disease Program
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationThe Body s Defenses CHAPTER 24
CHAPTER 24 The Body s Defenses PowerPoint Lectures for Essential Biology, Third Edition Neil Campbell, Jane Reece, and Eric Simon Essential Biology with Physiology, Second Edition Neil Campbell, Jane Reece,
More informationOxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients
Oxford University Hospitals NHS Trust Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis Information for patients page 2 What is Natalizumab and what is it used for? Natalizumab is an
More informationRecognition of T cell epitopes (Abbas Chapter 6)
Recognition of T cell epitopes (Abbas Chapter 6) Functions of different APCs (Abbas Chapter 6)!!! Directon Routes of antigen entry (Abbas Chapter 6) Flow of Information Barrier APCs LNs Sequence of Events
More informationCancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center
Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Bodnar s Law Simple Things are Important Very Simple Things are Very Important
More information